Natural Killer Cells Play Role in Ability of CML Patients to Discontinue TKIs
Patients with CML who have higher proportions of natural killer immune cells, and more mature natural killer cells, fare better when discontinuing therapy with imatinib. (Source: CancerNetwork)
Source: CancerNetwork - December 29, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Stopping Drug Therapy for CML: EURO-SKI Results Stopping Drug Therapy for CML: EURO-SKI Results
This is the largest cohort to date of patients with chronic myeloid leukemia followed after stopping treatment with tyrosine kinase inhibitors.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 6, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
At 2 Years, No CML Found in Half of Patients Who Stopped TKI Therapy
Cessation of tyrosine kinase inhibitor therapy may be possible in chronic myeloid leukemia patients with deep molecular response, according to the results of the Euro-Ski trial. (Source: CancerNetwork)
Source: CancerNetwork - December 4, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASH 2016 News Source Type: news
Global Health: Summer Project Turns Into Leukemia Testing Breakthrough
What began as a student effort at a lab in Seattle produced a test for chronic myeloid leukemia that works with a few spots of dried blood on a paper card. (Source: NYT Health)
Source: NYT Health - November 28, 2016 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Tests (Medical) Drugs (Pharmaceuticals) Leukemia Third World and Developing Countries Novartis AG Africa Gleevec Source Type: news
Bosutinib Offers Long-Term Efficacy in CML Patients Who Failed TKI Therapy
According to a long-term follow-up analysis of a phase I/II trial, bosutinib provides durable responses and a favorable toxicity profile in patients with chronic phase CML who are resistant/intolerant to other tyrosine kinase inhibitors. (Source: CancerNetwork)
Source: CancerNetwork - November 23, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Money in Medicine: Brian Druker on why he gets money from Gilead, not Gleevec
Dr. Brian Druker ’s name is practically synonymous with Gleevec, which is about as close as you can get to a miracle drug.
Yet Druker has never directly benefited from Gleevec, which has greatly expanded the life expectancy for those with chronic myeloid leukemia. Because he didn’t invent and patent the drug, h e receives no royalties.
He did give a couple of talks about it for drug maker Novartis, but then called it quits on those sorts of gigs.
“I decided it was not what I want to be doing,”… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 22, 2016 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news
Money in Medicine: Brian Druker on why he gets money from Gilead, not Gleevec
Dr. Brian Druker ’s name is practically synonymous with Gleevec, which is about as close as you can get to a miracle drug.
Yet Druker has never directly benefited from Gleevec, which has greatly expanded the life expectancy for those with chronic myeloid leukemia. Because he didn’t invent and patent the drug, h e receives no royalties.
He did give a couple of talks about it for drug maker Novartis, but then called it quits on those sorts of gigs.
“I decided it was not what I want to be doing,”… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 22, 2016 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news
PR1 Peptide Vaccine May Aid Leukemia Remission PR1 Peptide Vaccine May Aid Leukemia Remission
PR1 peptide vaccine may benefit many patients with myeloid leukemia, chronic myeloid leukemia and myelodysplastic syndrome, findings from an early clinical trial suggest.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 9, 2016 Category: Allergy & Immunology Tags: Public Health & Prevention News Source Type: news
Immune Cell Protein Expression Could Offer Predictive Biomarker in CML
Expression levels of CD62L and related immunologic markers are correlated with treatment responses and outcome in patients with CML, according to a new analysis. The markers could have prognostic value if validated in other cohorts. (Source: CancerNetwork)
Source: CancerNetwork - November 9, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Long-Term Follow-Up Shows Imatinib Discontinuation Remains Safe
The STIM1 study shows that patients with chronic myeloid leukemia who have undetectable minimal residual disease can safely discontinue imatinib therapy. (Source: CancerNetwork)
Source: CancerNetwork - October 4, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies News Source Type: news
High up-front costs could delay access to life-saving blood cancer drugs for Medicare patients
(UNC Lineberger Comprehensive Cancer Center) Researchers from the UNC Lineberger Comprehensive Cancer Center and collaborators report that nearly a third of a group of patients with chronic myeloid leukemia, and who have Medicare prescription drug insurance, did not start treatment within six months of diagnosis with any of three targeted drugs that have led to dramatic improvements in survival for the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 3, 2016 Category: Cancer & Oncology Source Type: news
Genetics Home Reference: chronic myeloid leukemia
https://ghr.nlm.nih.gov/condition/chronic-myeloid-leukemia (Source: NLM General Announcements)
Source: NLM General Announcements - September 28, 2016 Category: Databases & Libraries Source Type: news
Learning units launched to mark leukaemia day
Nursing Times has today launched new online education resources on haematological cancers known as myeloproliferative neoplasms to coincide with International Chronic Myeloid Leukaemia Day. (Source: Nursing Times)
Source: Nursing Times - September 22, 2016 Category: Nursing Source Type: news
EZH2 May Be Required for CML Initiation, Could Represent Therapeutic Target
A study found that the protein EZH2 is required for chronic myeloid leukemia initiating cells to survive. Inhibiting EZH2 could improve outcomes in TKI-resistant disease. (Source: CancerNetwork)
Source: CancerNetwork - September 19, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Discovery offers prospect of shorter treatment and cure for chronic myelogenous leukemia
(Dana-Farber Cancer Institute) Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia, patients generally must take them for the rest of their lives and may cease benefiting from them over time. In new research that could suggest a road to cure, scientists have found that CML stem cells die in response to inhibition of a protein called Ezh2. Drugs that target the protein are currently being tested in clinical trials for other cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2016 Category: Cancer & Oncology Source Type: news
